Michal Karas1, Katerina Steinerova2, Daniel Lysak2, Marcela Hrabetova2, Alexandra Jungova2, Jiri Sramek2, Pavel Jindra2, Jiri Polivka3,4, Lubos Holubec3. 1. Department of Haematology and Oncology, Faculty Hospital Plzen, Plzen, Czech Republic karas@fnplzen.cz. 2. Department of Haematology and Oncology, Faculty Hospital Plzen, Plzen, Czech Republic. 3. Biomedical Center, Faculty of Medicine in Plzen, Charles University Prague, Plzen, Czech Republic. 4. Department of Histology and Embryology, Faculty of Medicine in Plzen, Charles University Prague, Plzen, Czech Republic.
Abstract
BACKGROUND/AIM: Minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) before allogeneic hematopoietic stem cell transplantation (alloHSCT) can influence the results of therapy. With the aim of evaluating the potential role of pre-transplant MRD, we studied the impact of pre-transplant MRD level on the outcome of alloHSCT in patients with AML in complete remission (CR). PATIENTS AND METHODS: From 2/2005 to 9/2014, 60 patients with a median age of 54 years (range=30-66 years) with normal karyotype-AML harboring nucleophosmin 1 (NPM1) mutation [53% Fms-related tyrosine kinase receptor 3 internal tandem duplication (FLT3/ITD)-positive] in first (n=45) or second (n=15) CR underwent myeloablative (n=16) or reduced-intensity (n=44) alloHSCT (27% related, 73% unrelated). The MRD level was determined from bone marrow samples using real-time polymerase chain reaction for detection of NPM1 mutations before starting the conditioning regimen. RESULTS: The estimated probabilities of 3-year relapse, event-free survival (EFS) and overall survival (OS) for the whole cohort were 28%, 54%, and 59%, respectively. Statistical analysis showed that only age over 63 years and high MRD level affected alloHSCT outcome. Pre-transplant MRD level of 10 mutant copies of NPM1 per 10,000 Abelson murine leukemia viral oncogene homolog 1 (ABL) copies had the strongest statistical significance, and detection of higher MRD level (>10 NPM1-mutant copies) before alloHSCT was associated with increased overall mortality (hazard ratio=3.71; 95% confidence interval=1.55-9.06; p=0.004). The estimated probabilities of 3-year relapse, EFS, and OS were 6%, 72%, and 75% for patients with a low level of MRD and 48%, 35%, and 40% for patients with a higher level. CONCLUSION: Our data showed that the pre-transplant level of MRD in patients with normal karyotype AML harboring NPM1 mutation in CR provides important prognostic information, which as an independent prognostic factor predicts transplant results. Copyright
BACKGROUND/AIM: Minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) before allogeneic hematopoietic stem cell transplantation (alloHSCT) can influence the results of therapy. With the aim of evaluating the potential role of pre-transplant MRD, we studied the impact of pre-transplant MRD level on the outcome of alloHSCT in patients with AML in complete remission (CR). PATIENTS AND METHODS: From 2/2005 to 9/2014, 60 patients with a median age of 54 years (range=30-66 years) with normal karyotype-AML harboring nucleophosmin 1 (NPM1) mutation [53% Fms-related tyrosine kinase receptor 3 internal tandem duplication (FLT3/ITD)-positive] in first (n=45) or second (n=15) CR underwent myeloablative (n=16) or reduced-intensity (n=44) alloHSCT (27% related, 73% unrelated). The MRD level was determined from bone marrow samples using real-time polymerase chain reaction for detection of NPM1 mutations before starting the conditioning regimen. RESULTS: The estimated probabilities of 3-year relapse, event-free survival (EFS) and overall survival (OS) for the whole cohort were 28%, 54%, and 59%, respectively. Statistical analysis showed that only age over 63 years and high MRD level affected alloHSCT outcome. Pre-transplant MRD level of 10 mutant copies of NPM1 per 10,000 Abelson murine leukemia viral oncogene homolog 1 (ABL) copies had the strongest statistical significance, and detection of higher MRD level (>10 NPM1-mutant copies) before alloHSCT was associated with increased overall mortality (hazard ratio=3.71; 95% confidence interval=1.55-9.06; p=0.004). The estimated probabilities of 3-year relapse, EFS, and OS were 6%, 72%, and 75% for patients with a low level of MRD and 48%, 35%, and 40% for patients with a higher level. CONCLUSION: Our data showed that the pre-transplant level of MRD in patients with normal karyotype AML harboring NPM1 mutation in CR provides important prognostic information, which as an independent prognostic factor predicts transplant results. Copyright
Authors: Felicitas Thol; Razif Gabdoulline; Alessandro Liebich; Piroska Klement; Johannes Schiller; Christian Kandziora; Lothar Hambach; Michael Stadler; Christian Koenecke; Madita Flintrop; Mira Pankratz; Martin Wichmann; Blerina Neziri; Konstantin Büttner; Bennet Heida; Sabrina Klesse; Anuhar Chaturvedi; Arnold Kloos; Gudrun Göhring; Brigitte Schlegelberger; Verena I Gaidzik; Lars Bullinger; Walter Fiedler; Albert Heim; Iyas Hamwi; Matthias Eder; Jürgen Krauter; Richard F Schlenk; Peter Paschka; Konstanze Döhner; Hartmut Döhner; Arnold Ganser; Michael Heuser Journal: Blood Date: 2018-09-06 Impact factor: 22.113
Authors: Ing S Tiong; Richard Dillon; Adam Ivey; Tse-Chieh Teh; Phillip Nguyen; Nicholas Cummings; David C Taussig; Annie-Louise Latif; Nicola E Potter; Manohursingh Runglall; Nigel H Russell; Kavita Raj; Anthony P Schwarer; Chun Yew Fong; Andrew P Grigg; Andrew H Wei Journal: Br J Haematol Date: 2020-05-26 Impact factor: 6.998
Authors: Petra Kövy; Zoltán Őrfi; András Bors; András Kozma; László Gopcsa; János Dolgos; Nóra Lovas; József Harasztdombi; Viktor Lakatos; Ágnes Király; Gábor Mikala; István Vályi-Nagy; Péter Reményi; Hajnalka Andrikovics Journal: PLoS One Date: 2021-06-21 Impact factor: 3.752